Home » Stocks » SLRX

Salarius Pharmaceuticals, Inc. (SLRX)

Stock Price: $0.684 USD -0.001 (-0.15%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.699 +0.015 (2.19%) Nov 27, 4:35 PM

Stock Price Chart

Key Info

Market Cap 10.01M
Revenue (ttm) 4.79M
Net Income (ttm) -7.47M
Shares Out 19.84M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $0.684
Previous Close $0.685
Change ($) -0.001
Change (%) -0.15%
Day's Open 0.688
Day's Range 0.657 - 0.700
Day's Volume 278,237
52-Week Range 0.555 - 4.980

More Stats

Market Cap 10.01M
Enterprise Value 1.22M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 19.84M
Float n/a
EPS (basic) -0.89
EPS (diluted) -0.66
FCF / Share -0.64
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 585,014
Short Ratio 4.47
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.09
PB Ratio 0.66
Revenue 4.79M
Operating Income -8.09M
Net Income -7.47M
Free Cash Flow -11.57M
Net Cash 8.80M
Net Cash / Share 0.60
Gross Margin -11.56%
Operating Margin -168.77%
Profit Margin -155.80%
FCF Margin -241.48%
ROA -19.92%
ROE -49.22%
ROIC -1,542.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(543.27% upside)
Current: $0.684
Target: 4.40
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth77.57%5.37%83.24%--
Gross Profit3.471.951.850.35-
Operating Income-8.27-1.68-1.75-39.89-29.21
Net Income-6.94-1.67-1.75-39.49-29.14
Shares Outstanding3.271.541.150.650.56
Earnings Per Share-2.12-1.16-1.60-60.75-52.00
Operating Cash Flow-11.584.18-1.46-32.05-20.75
Capital Expenditures----0.55-0.27
Free Cash Flow-11.584.18-1.46-32.61-21.01
Cash & Equivalents3.746.130.5261.2091.47
Total Debt0.50----
Net Cash / Debt3.246.130.5261.2091.47
Book Value10.58-1.27-2.9059.3292.19
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Salarius Pharmaceuticals, Inc.
Country United States
Employees 7
CEO David J. Arthur

Stock Information

Ticker Symbol SLRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SLRX


Salarius Pharmaceuticals a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.